These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
107 related articles for article (PubMed ID: 34608874)
1. Zinc Finger Protein 24 is a Prognostic Factor in Ovarian Serous Carcinoma. Chen J; Guo J; Yuan Y; Wang Y Appl Immunohistochem Mol Morphol; 2022 Feb; 30(2):136-144. PubMed ID: 34608874 [TBL] [Abstract][Full Text] [Related]
2. Prognostic Role of Zinc Finger Homeobox 4 in Ovarian Serous Cystadenocarcinoma. Ha M; Kim J; Park SM; Hong CM; Han ME; Song P; Kang CD; Lee D; Kim YH; Hur J; Oh SO Genet Test Mol Biomarkers; 2020 Mar; 24(3):145-149. PubMed ID: 32105524 [No Abstract] [Full Text] [Related]
3. Identification and validation of a prognostic index based on a metabolic-genomic landscape analysis of ovarian cancer. Zhang QF; Li YK; Chen CY; Zhang XD; Cao L; Quan FF; Zeng X; Wang J; Liu J Biosci Rep; 2020 Sep; 40(9):. PubMed ID: 32880385 [TBL] [Abstract][Full Text] [Related]
4. Expression of Inorganic Pyrophosphatase (PPA1) Correlates with Poor Prognosis of Epithelial Ovarian Cancer. Li H; Xiao N; Li Z; Wang Q Tohoku J Exp Med; 2017 Feb; 241(2):165-173. PubMed ID: 28202851 [TBL] [Abstract][Full Text] [Related]
5. Pair Box 8 (PAX8) protein expression in high grade, late stage (stages III and IV) ovarian serous carcinoma. Mhawech-Fauceglia P; Wang D; Samrao D; Godoy H; Ough F; Liu S; Pejovic T; Lele S Gynecol Oncol; 2012 Oct; 127(1):198-201. PubMed ID: 22705448 [TBL] [Abstract][Full Text] [Related]
6. A five-DNA methylation signature act as a novel prognostic biomarker in patients with ovarian serous cystadenocarcinoma. Guo W; Zhu L; Yu M; Zhu R; Chen Q; Wang Q Clin Epigenetics; 2018 Nov; 10(1):142. PubMed ID: 30446011 [TBL] [Abstract][Full Text] [Related]
7. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906 [TBL] [Abstract][Full Text] [Related]
8. Dickkopf-1 is frequently overexpressed in ovarian serous carcinoma and involved in tumor invasion. Wang S; Zhang S Clin Exp Metastasis; 2011 Aug; 28(6):581-91. PubMed ID: 21607803 [TBL] [Abstract][Full Text] [Related]
9. MiRNA expression signature for potentially predicting the prognosis of ovarian serous carcinoma. Yu X; Zhang X; Bi T; Ding Y; Zhao J; Wang C; Jia T; Han D; Guo G; Wang B; Jiang J; Cui S Tumour Biol; 2013 Dec; 34(6):3501-8. PubMed ID: 23836287 [TBL] [Abstract][Full Text] [Related]
10. Identification of core genes for early diagnosis and the EMT modulation of ovarian serous cancer by bioinformatics perspective. Zhang Y; Wang X; Chen X Aging (Albany NY); 2021 Jan; 13(2):3112-3145. PubMed ID: 33493131 [TBL] [Abstract][Full Text] [Related]
11. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray. Wang S; Yin C; Zhang Y; Zhang L; Tao L; Liang W; Pang L; Fu R; Ding Y; Li F; Jia W Biomed Res Int; 2019; 2019():2867372. PubMed ID: 31312656 [TBL] [Abstract][Full Text] [Related]
12. Expression of EphB6 in ovarian serous carcinoma is associated with grade, TNM stage and survival. Gu Y; Li F; Qian N; Chen X; Wang H; Wang J J Clin Pathol; 2016 May; 69(5):448-53. PubMed ID: 26468391 [TBL] [Abstract][Full Text] [Related]
13. SALL4 is a marker of poor prognosis in serous ovarian carcinoma promoting invasion and metastasis. Yang M; Xie X; Ding Y Oncol Rep; 2016 Mar; 35(3):1796-806. PubMed ID: 26750614 [TBL] [Abstract][Full Text] [Related]
14. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma]. Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967 [No Abstract] [Full Text] [Related]
15. Tissue HE4 Expression Discriminates the Ovarian Serous Carcinoma but Not the Uterine Serous Carcinoma Patients. A New Adjunct to the Origin of the Tumor Site. Celik B; Bulut T; Yalcin AD Pathol Oncol Res; 2020 Apr; 26(2):1145-1151. PubMed ID: 31165997 [TBL] [Abstract][Full Text] [Related]
17. Expression of Cox-2, CD34, Bcl-2, and p53 and survival in patients with primary peritoneal serous carcinoma and primary ovarian serous carcinoma. Khalifeh I; Munkarah AR; Lonardo F; Malone JM; Morris R; Lawrence WD; Ali-Fehmi R Int J Gynecol Pathol; 2004 Apr; 23(2):162-9. PubMed ID: 15084845 [TBL] [Abstract][Full Text] [Related]
18. PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma. Kim KH; Choi KU; Kim A; Lee SJ; Lee JH; Suh DS; Kwon BS; Hwang C J Ovarian Res; 2019 Jun; 12(1):56. PubMed ID: 31208449 [TBL] [Abstract][Full Text] [Related]
19. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma. Al-Hussaini M; Stockman A; Foster H; McCluggage WG Histopathology; 2004 Feb; 44(2):109-15. PubMed ID: 14764054 [TBL] [Abstract][Full Text] [Related]
20. The impact of c-kit and ki-67 expression on patients prognosis in advanced ovarian serous carcinoma. Khalifeh I; Munkarah AR; Schimp V; Morris R; Lawrence WD; Ali-Fehmi R Int J Gynecol Pathol; 2005 Jul; 24(3):228-34. PubMed ID: 15968197 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]